Company intelligence / Profile preview

CepTor

Ownership: Private
Development stage: Other

Overview

CepTor was a development-stage biopharmaceutical company focused on the discovery and development of proprietary, cell-targeted therapeutics. Its lead program was Myodur for muscular dystrophy. The company had entered into an exclusive license agreement with JCR Pharmaceuticals for Myodur in the Pacific Rim and was set to receive milestone payments upon IND filing. No clinical results or later-stage data are available in public records.

Therapeutic areas: Neurology
Modalities: Small moleculeProtein
Industry: Biotech

Drug pipeline

2 assets

L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

JCR Pharmaceuticals (exclusive license agreement for Myodur in muscular dystrophy in the Pacific Rim)

Beyond the preview

Go deeper on CepTor.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CepTor.

Explore the full profile